Journals and Research

Research and education are foundational to the mission of Orlando Health and our Cancer Institute. As frequent contributors to leading publications, our physicians share their research and clinical insights with a national and international community of colleagues.

RSS Feed

Author(s) Title Description Publish Date
Timothy D Solberg, Nzhde Agazaryan, Mark De Ridder, Isabelle Germano, Naren Ramakrishna, James Robar, Ronald Warnick, Reinhard Wurm, Antonia Wurmseher Credentialing of stereotactic radiosurgery and stereotactic body radiation therapy programs for quality and safety The Novalis Certified Program The expectation of quality and safety is a fundamental tenet in all areas of healthcare, and a cornerstone of best practice is a process of continuous learning and continuous improvement. Independent audits and peer review of radiotherapy programs are an important mechanism for identifying process o... 8/1/2024
Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, Anna Spreafico, Melanie Nordlinger, Andrea Viviana Pastor, Erin Alesi, Anterpreet Neki, Andrea S Fung, Iane Pinto Figueiredo Lima, Peter Oppelt, Geraldo Felicio da Cunha Junior, Barbara Burtness, Fabio Andre Franke, Jennifer E Tseng, Abhishek Joshi, Joy McCarthy, Ramona Swaby, Yulia Sidi, Burak Gumuscu, Niroshini Naicker, Gilberto de Castro Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for RecurrentMetastatic Head and Neck Squamous Cell Carcinoma KEYNOTE-B10 A Single-Arm Phase IV Trial CONCLUSION: Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population. 7/22/2024
Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos, John Crown, Tae Min Kim, Dae Ho Lee, Sajeve S Thomas, Janice Mehnert, John Kaczmar, Nehal J Lakhani, Kevin B Kim, Mark R Middleton, Guilherme Rabinowits, Alexander I Spira, Melinda Yushak, Inderjit Mehmi, Fang Fang, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Fang Wang, Nathalie Fiaschi, Laura Brennan, Anne Paccaly, Sheila Masinde, Mark Salvati, Matthew G Fury, Glenn Kroog, Israel Lowy, Giuseppe Gullo Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 LAG-3 Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma CONCLUSION: The current results show a promising benefit-risk profile of fianlimab/cemiplimab combination for patients with advanced melanoma, including those with previous anti-PD-1 therapy in the adjuvant, but not advanced, setting. 6/20/2024
Vincent S Alexander, Michael Ernst, Wang L Cheung, Alyssa N Obermiller, Catherine Mercado, Hermes Garcia, Kavita M Pattani High-Grade Atypical TeratoidRhabdoid Tumor in the Pituitary Region Atypical teratoid/rhabdoid tumors (AT/RTs) are embryological tumors of the central nervous system (CNS). They are typically found in children, with rare presentations in adults. We describe the presentation of an AT/RT in the pituitary region of a 37-year-old female. The patient presented with a two... 3/15/2024
Amy I Laughlin, Quy Cao, Richard Bryson, Virginia Haughey, Rashad Abdul-Salaam, Virgilio Gonzenbach, Mridini Rudraraju, Igor Eydman, Christopher M Tweed, Glenn J Fala, Kash Patel, Kevin R Fox, C William Hanson, Justin E Bekelman, Haochang Shou Detection of Medication Taking Using a Wrist-Worn Commercially Available Wearable Device CONCLUSION: These results in a patient-specific population are exemplar of the potential to measure real-time medication adherence using a wrist-worn commercially available wearable device. 12/21/2023
Daniel S Oh, Marzieh Ershad, Jon O Wee, Manu Suraj Sancheti, Desmond M D'Souza, Luis Javier Herrera, Lana Y Schumacher, Mallory Shields, Kristen Brown, Sadia Yousaf, John F Lazar Comparison of Global Evaluative Assessment of Robotic Surgery with objective performance indicators for the assessment of skill during robotic-assisted thoracic surgery CONCLUSION: There was a relatively poor overall correlation between the Global Evaluative Assessment of Robotic Skills and objective performance indicators. However, both appear strongly correlated for certain metrics such as efficiency and smoothness. Objective performance indicators may be a poten... 9/17/2023
Laura Goyack, Gurjot Garcha, Ruchir Shah, Yahaira Ortiz Gonzalez, Mark Vollenweider, Mohammad Salimian, Wang Cheung Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma A 51-year-old male with uncontrolled asthma and recent convalescence from severe acute respiratory syndrome coronavirus-2c pneumonia presented with cough, dyspnea, and chest pain. Evaluation revealed significant peripheral eosinophilia, elevated troponin, and biventricular failure resulting in cardi... 9/6/2023
Thomas J Herzog, John L Hays, Joyce N Barlin, Joseph Buscema, Noelle G Cloven, Lynn R Kong, Nidhi Kumar Tyagi, Grainger S Lanneau, Beverly J Long, Robert L Marsh, Shelly M Seward, David C Starks, Stephen Welch, Kathleen N Moore, Panagiotis A Konstantinopoulos, Lucy Gilbert, Bradley J Monk, David M O'Malley, Xiwei Chen, Rita Dalal, Robert L Coleman, Jalid Sehouli ARTISTRY-7 phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer Standard single-agent nonplatinum chemotherapy provides only modest benefit in a small proportion of patients with platinum-resistant/-refractory ovarian cancer, with objective response rates of 6-20% and progression-free survival of ≈3-4 months. Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel ... 6/19/2023
Michael S Kent, Matthew G Hartwig, Eric Vallières, Abbas E Abbas, Robert J Cerfolio, Mark R Dylewski, Thomas Fabian, Luis J Herrera, Kimble G Jett, Richard S Lazzaro, Bryan Meyers, Rishindra M Reddy, Michael F Reed, David C Rice, Patrick Ross, Inderpal S Sarkaria, Lana Y Schumacher, Lawrence N Spier, William B Tisol, Dennis A Wigle, Michael Zervos Pulmonary Open, Robotic, and Thoracoscopic Lobectomy PORTaL Study Survival Analysis of 6646 Cases CONCLUSIONS: Our finding from this large multicenter study suggests that patients undergoing RL and OL have statistically similar OS, while the VATS group was associated with shorter OS. Further studies with longer follow-up are necessary to help evaluate these observations. 2/10/2023
Amy I Laughlin, Tingting Li, Qingzhao Yu, Xiao-Cheng Wu, Yong Yi, Mei-Chin Hsieh, William Havron, Margo Shoup, Quyen D Chu Impact of Medicaid Expansion on Breast Cancer Diagnosis and Treatment in Southern States CONCLUSIONS: Unlike NMES, MES experienced increased Medicaid insured, increased treatment, and decreased distant-stage disease at diagnosis. Medicaid expansion in the South leads to earlier and more comprehensive treatment of breast cancer. 2/1/2023
Luis J Herrera, Lana Y Schumacher, Matthew G Hartwig, Charles T Bakhos, Rishindra M Reddy, Eric Vallières, Michael S Kent Pulmonary Open, Robotic, and Thoracoscopic Lobectomy study Outcomes and risk factors of conversion during minimally invasive lobectomy CONCLUSIONS: Converted minimally invasive lobectomies were not associated with worse perioperative mortality compared with open lobectomy. Compared with VATS lobectomy, RL is associated with a lower probability of conversion in this propensity-score matched cohort study. 12/12/2022
Michael D Chuong, Mary Ann Clark, Lauren E Henke, Amar U Kishan, Lorraine Portelance, Parag J Parikh, Michael F Bassetti, Himanshu Nagar, Stephen A Rosenberg, Minesh P Mehta, Tamer Refaat, Justin M Rineer, Adam Smith, Steven Seung, Bassem I Zaki, Martin Fuss, Raymond H Mak Patterns of utilization and clinical adoption of 035 Tesla MR-guided radiation therapy in the United States - Understanding the transition to adaptive, ultra-hypofractionated treatments CONCLUSIONS: This is the first comprehensive study reporting patterns of utilization among early adopters of MRIdian in the US. Intrafraction MR image-guidance, advanced motion management, and increasing adoption of adaptive radiation therapy has led to a substantial transition to ultra-hypofraction... 12/5/2022
Aiste Dobrovolskaite, Holly Moots, Mukund P Tantak, Kunal Shah, Jenna Thomas, Sharifa Dinara, Chelsea Massaro, Paul M Hershberger, Patrick R Maloney, Satyamaheshwar Peddibhotla, Eliot Sugarman, Sally Litherland, Juan Pablo Arnoletti, Rajiv Kumar Jha, David Levens, Otto Phanstiel Discovery of Anthranilic Acid Derivatives as Difluoromethylornithine Adjunct Agents That Inhibit Far Upstream Element Binding Protein 1 FUBP1 Function Polyamine biosynthesis is regulated by ornithine decarboxylase (ODC), which is transcriptionally activated by c-Myc. A large library was screened to find molecules that potentiate the ODC inhibitor, difluoromethylornithine (DFMO). Anthranilic acid derivatives were identified as DFMO adjunct agents. ... 11/16/2022
Omar A Zeidan, Ethan Pepmiller, Twyla Willoughby, Zhiqiu Li, James Burkavage, Brian Harper, Michael Fraser, Katie Moffatt, Sanford L Meeks, Naren Ramakrishna Operational Performance of a Compact Proton Therapy System A 5-Year Experience CONCLUSION: Our data show that this compact system is versatile, robust, and capable of delivering complex treatments like a large full-gantry system. Utilization data show that a fraction of all subcomponents range of angular motion has been used. Compilation of beam-specific metrics, such as range... 9/5/2022
Michael Padgett, Shivam M Kharod, Catherine E Mercado, Christopher G Morris, Michael S Rutenberg, Romaine C Nichols Patterns-of-care disparities among uninsured versus insured patients with anorectal carcinoma referred for radiotherapy at an Urban Safety-Net Hospital CONCLUSIONS: Differences in health insurance status demonstrated various disparities in patterns-of-care, including significant delay in diagnosis, more advanced-stage disease at presentation, and treatment initiation delays among UPs. Nevertheless, overall survival at 5 years was not statistically ... 7/15/2022
Sharon H Giordano, Maria Alice B Franzoi, Sarah Temin, Carey K Anders, Sarat Chandarlapaty, Jennie R Crews, Jeffrey J Kirshner, Ian E Krop, Nancy U Lin, Aki Morikawa, Debra A Patt, Jane Perlmutter, Naren Ramakrishna, Nancy E Davidson Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer ASCO Guideline Update PURPOSE: To update evidence-based guideline recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer. 5/31/2022
Naren Ramakrishna, Carey K Anders, Nancy U Lin, Aki Morikawa, Sarah Temin, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Maria Alice B Franzoi, Jeffrey J Kirshner, Ian E Krop, Debra A Patt, Jane Perlmutter, Sharon H Giordano Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases ASCO Guideline Update PURPOSE: To provide updated evidence- and consensus-based guideline recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer up to 2021. 5/31/2022
Mirza Zain Baig, Syed S Razi, Kojo Agyabeng-Dadzie, Stephanie Stroever, Zaid Muslim, Joanna Weber, Luis J Herrera, Faiz Y Bhora Robotic-assisted thoracoscopic surgery demonstrates a lower rate of conversion to thoracotomy than video-assisted thoracoscopic surgery for complex lobectomies CONCLUSIONS: Our analysis of the National Cancer Database suggests that robotic lobectomy for complex lung resections achieves similar perioperative outcomes and R0 resections as VATS lobectomy with the exception of a lower rate of conversion to thoracotomy. 5/11/2022
Zaid Muslim, Stephanie Stroever, Kostantinos Poulikidis, Joanna F Weber, Cliff P Connery, Luis J Herrera, Faiz Y Bhora Conversion to Thoracotomy in Non-Small Cell Lung Cancer Risk Factors and Perioperative Outcomes Objective: We aimed to identify predictors of conversion to thoracotomy and test the hypothesis that conversion is associated with inferior perioperative outcomes in non-small cell lung cancer (NSCLC). Methods: We queried the National Cancer Database for patients with stage I to III NSCLC undergoing... 5/2/2022
Christopher A French, Michael L Cheng, Glenn J Hanna, Steven G DuBois, Nicole G Chau, Christine L Hann, Simone Storck, Ravi Salgia, Matteo Trucco, Jennifer Tseng, Anastasios Stathis, Richard Piekarz, Ulrich M Lauer, Christophe Massard, Kelly Bennett, Shodeinde Coker, Ulrike Tontsch-Grunt, Martin L Sos, Sida Liao, Catherine J Wu, Kornelia Polyak, Sarina A Piha-Paul, Geoffrey I Shapiro Report of the First International Symposium on NUT Carcinoma NUT carcinoma is a rare, aggressive cancer defined by rearrangements of the NUTM1 gene. No routinely effective treatments of NUT carcinoma exist, despite harboring a targetable oncoprotein, most commonly BRD4-NUT. The vast majority of cases are fatal. Poor awareness of the disease is a major obstacl... 4/13/2022
Cameron W Swanick, Jing Jiang, J Alberto Maldonado, Xiudong Lei, Ya-Chen Tina Shih, Abigail S Caudle, Donald P Baumann, Sharon H Giordano, Simona F Shaitelman, Shervin M Shirvani, Benjamin D Smith Differences in Time Burden across Local Therapy Strategies for Early-stage Breast Cancer CONCLUSIONS: Although Mast+Recon confers the highest inpatient and outpatient time burden, Lump+WBI carries the highest total time burden. Increased use of hypofractionation will reduce the total time burden for Lump+WBI. 11/8/2021
Curtis M Bryant, Randal H Henderson, R Charles Nichols, William M Mendenhall, Bradford S Hoppe, Carlos E Vargas, Thomas B Daniels, C Richard Choo, Rahul R Parikh, Huan Giap, Jerry D Slater, Neha Vapiwala, William Barrett, Akash Nanda, Mark V Mishra, Seungtaek Choi, Jay J Liao, Nancy P Mendenhall, Genitourinary Subcommittee of the Particle Therapy Co-Operative Group Consensus Statement on Proton Therapy for Prostate Cancer Proton therapy is a promising but controversial treatment in the management of prostate cancer. Despite its dosimetric advantages when compared with photon radiation therapy, its increased cost to patients and insurers has raised questions regarding its value. Multiple prospective and retrospective ... 11/1/2021
Sanford L Meeks, Catherine E Mercado, Richard A Popple, Nzhde Agazaryan, Tania Kaprealian, John B Fiveash, Stephen Tenn Practical Considerations for Single Isocenter LINAC Radiosurgery of Multiple Brain Metastases The purpose of this paper is to summarize treatment guidelines for the performance of single isocenter LINAC radiosurgery of multiple brain metastases developed and used by 3 experienced centers. This article is not meant to provide consensus guidelines. Rather, this is a practical, "how we do it" r... 10/7/2021
Michael S Kent, Matthew G Hartwig, Eric Vallières, Abbas E Abbas, Robert J Cerfolio, Mark R Dylewski, Thomas Fabian, Luis J Herrera, Kimble G Jett, Richard S Lazzaro, Bryan Meyers, Brian A Mitzman, Rishindra M Reddy, Michael F Reed, David C Rice, Patrick Ross, Inderpal S Sarkaria, Lana Y Schumacher, William B Tisol, Dennis A Wigle, Michael Zervos Pulmonary Open, Robotic, and Thoracoscopic Lobectomy PORTaL Study An Analysis of 5721 Cases CONCLUSIONS: RL and VATS approaches were associated with favorable perioperative outcomes compared to OL. Robotic-assisted lobectomy was also associated with a reduced length of stay and decreased conversion rate when compared to VATS. 9/17/2021
Luis J Herrera, Eric M Wherley, Kojo Agyabeng-Dadzie, Bhupaul Ramsuchit, Matthew A Johnston, Juan C Escalon 500 Consecutive Robotic Lobectomies for Non-Small Cell Lung Cancer Perioperative and Oncologic Outcomes CONCLUSIONS: Robotic lobectomy for lung cancer is a feasible technique for treatment of non-small cell lung cancer with low perioperative morbidity and mortality. Furthermore, excellent oncologic outcomes can be achieved with this approach. 8/5/2021
Ji Young Bang, C Mel Wilcox, Juan Pablo Arnoletti, Shajan Peter, John Christein, Udayakumar Navaneethan, Robert Hawes, Shyam Varadarajulu Validation of the Orlando Protocol for endoscopic management of pancreatic fluid collections in the era of lumen-apposing metal stents CONCLUSIONS: A structured approach integrating LAMS with selective use of plastic stents improved treatment success in patients with PFCs compared to an approach using only plastic stents. 7/31/2021
Julius K Weng, Xiudong Lei, Pamela Schlembach, Elizabeth S Bloom, Simona F Shaitelman, Isidora Y Arzu, Gregory Chronowski, Tomas Dvorak, Emily Grade, Karen Hoffman, George Perkins, Valerie K Reed, Shalin J Shah, Michael C Stauder, Eric A Strom, Welela Tereffe, Wendy A Woodward, Gabriel N Hortobagyi, Kelly K Hunt, Thomas A Buchholz, Benjamin D Smith Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation CONCLUSIONS: Both CF-WBI and HF-WBI confer similar longitudinal PROs and physician-rated cosmesis through 5 years of follow-up, with no relevant subsets that fared better with CF-WBI. This evidence supports broad adoption of hypofractionation with boost, including in patients receiving chemotherapy ... 5/16/2021
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina, Harriet M Kluger, Sajeve S Thomas, Evidio Domingo-Musibay, Anna C Pavlick, Eric D Whitman, Salvador Martin-Algarra, Pippa Corrie, Brendan D Curti, Judit Oláh, Jose Lutzky, Jeffrey S Weber, James M G Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cecile Chartier, Friedrich Graf Finckenstein, Maria Fardis, John M Kirkwood, Jason A Chesney Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma CONCLUSION: Lifileucel demonstrated durable responses and addresses a major unmet need in patients with metastatic melanoma with limited treatment options after approved therapy, including the primary refractory to anti-PD-1 or PD-L1 therapy subset. 5/12/2021
Yehuda Galili, Ahmad El-Far, Jennifer Tseng, Steve Carlan Role of immunotherapy in oligometastatic nonsmall cell lung cancer The approach to metastatic lung cancer has long been focused on palliation therapy and comfort care. Recently, significant subsets of patients who suffer from a limited form of the disease have shown curative outcomes. The oligometastatic disease theory was first introduced in 1995, and since has be... 5/11/2021
Shivam M Kharod, Catherine E Mercado, Christopher G Morris, Curtis M Bryant, Nancy P Mendenhall, William M Mendenhall, R Charles Nichols, Bradford S Hoppe, Xiaoying Liang, Zhong Su, Zuofeng Li, Randal H Henderson Postoperative or Salvage Proton Radiotherapy for Prostate Cancer After Radical Prostatectomy CONCLUSION: High-dose postprostatectomy proton therapy provides effective long-term biochemical control and freedom from metastasis, with low acute and long-term gastrointestinal and genitourinary toxicity. 4/8/2021
Jennifer B Permuth, Kaleena B Dezsi, Shraddha Vyas, Karla N Ali, Toni L Basinski, Ovie A Utuama, Jason W Denbo, Jason Klapman, Aamir Dam, Estrella Carballido, Dae Won Kim, Jose M Pimiento, Benjamin D Powers, Amy K Otto, Jung W Choi, Dung-Tsa Chen, Jamie K Teer, Francisca Beato, Alina Ward, Elena M Cortizas, Suzanne Y Whisner, Iverson E Williams, Andrea N Riner, Kenneth Tardif, Vic Velanovich, Andreas Karachristos, Wade G Douglas, Adrian Legaspi, Bassan J Allan, Kenneth Meredith, Manual A Molina-Vega, Philip Bao, Jamii St Julien, Kevin L Huguet, Lee Green, Folakemi T Odedina, Nagi B Kumar, Vani N Simmons, Thomas J George, Susan T Vadaparampil, Pamela J Hodul, J Pablo Arnoletti, Ziad T Awad, Debashish Bose, Kun Jiang, Barbara A Centeno, Clement K Gwede, Mokenge Malafa, Sarah M Judge, Andrew R Judge, Daniel Jeong, Mark Bloomston, Nipun B Merchant, Jason B Fleming, Jose G Trevino, None On Behalf Of The Florida Pancreas Collaborative The Florida Pancreas Collaborative Next-Generation Biobank Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer Background: Well-annotated, high-quality biorepositories provide a valuable platform to support translational research. However, most biorepositories have poor representation of minority groups, limiting the ability to address health disparities. Methods: We describe the establishment of the Florida... 3/6/2021
Tien Anh N Tran, Armando Rosales, J Pablo Arnoletti, Jie Ouyang, Muhammad K Hasan Concomitant neuroendocrine tumor and gastrointestinal stromal tumor in a duodenal fine needle aspiration A cytologic clue for neurofibromatosis type 1 The identification of two cell populations displaying different cytologic characteristics in the same fine needle aspiration (FNA), one with an epithelioid appearance and the other spindle cell morphology, is an extremely rare phenomenon and potentially represents a source of diagnostic confusion. D... 12/6/2020
Dao M Nguyen, Inderpal S Sarkaria, Chao Song, Rishindra M Reddy, Nestor Villamizar, Luis J Herrera, Lu Shi, Emelline Liu, David Rice, Daniel S Oh Clinical and economic comparative effectiveness of robotic-assisted, video-assisted thoracoscopic, and open lobectomy CONCLUSIONS: During the study period, the utilization of RL increased substantially and was associated with improved perioperative outcomes compared with VL and OL. When annual hospital volume was >25 cases, these clinical advantages persisted and there was no significant cost difference between RL,... 4/11/2020
Benjamin D Smith, Xiudong Lei, Kevin Diao, Ying Xu, Yu Shen, Grace L Smith, Sharon H Giordano, Sarah M DeSnyder, Kelly K Hunt, Mediget Teshome, Reshma Jagsi, Simona F Shaitelman, Susan K Peterson, Cameron W Swanick Effect of Surgeon Factors on Long-Term Patient-Reported Outcomes After Breast-Conserving Therapy in Older Breast Cancer Survivors CONCLUSIONS: Specialized surgical oncology training is associated with improved long-term patient-reported outcomes. These findings underscore the value of specialized training and may be useful to patients choosing their care team. 1/10/2020
Meghan Sri Karuturi, Xiudong Lei, Yu Shen, Sharon H Giordano, Cameron W Swanick, Benjamin D Smith Long-term decision regret surrounding systemic therapy in older breast cancer survivors A population-based survey study INTRODUCTION: Little is known regarding regret experienced by older breast cancer survivors surrounding the choice for adjuvant systemic therapy, which limits providers' ability to optimally engage in the shared decision-making process. To address this, we evaluated endocrine therapy and chemotherap... 4/4/2019
Pragati G Advani, Xiudong Lei, Cameron W Swanick, Ying Xu, Yu Shen, Nathan A Goodwin, Grace L Smith, Sharon H Giordano, Kelly K Hunt, Reshma Jagsi, Benjamin D Smith Local Therapy Decisional Regret in Older Women With Breast Cancer A Population-Based Study CONCLUSIONS: Local therapy regret afflicts nearly one quarter of our cohort of older breast cancer survivors, and it is associated with black race, less education, and more extensive nodal dissection, but not breast surgery. Regret is distinct from health utility, suggesting that it is a unique psyc... 2/5/2019
Ji Young Bang, Juan Pablo Arnoletti, Bronte A Holt, Bryce Sutton, Muhammad K Hasan, Udayakumar Navaneethan, Nicholas Feranec, C Mel Wilcox, Benjamin Tharian, Robert H Hawes, Shyam Varadarajulu An Endoscopic Transluminal Approach, Compared With Minimally Invasive Surgery, Reduces Complications and Costs for Patients With Necrotizing Pancreatitis CONCLUSIONS: In a randomized trial of 66 patients, an endoscopic transluminal approach for infected necrotizing pancreatitis, compared with minimally invasive surgery, significantly reduced major complications, lowered costs, and increased quality of life. Clinicaltrials.gov no: NCT02084537. 11/20/2018
Neige Journy, Daniel J Indelicato, Diana R Withrow, Tetsuo Akimoto, Claire Alapetite, Masayuki Araya, Andrew Chang, John Han-Chih Chang, Brian Chon, Michael E Confer, Yusuke Demizu, Rémi Dendale, Jérôme Doyen, Ralph Ermoian, Kristin Gurtner, Christine Hill-Kayser, Hiromitsu Iwata, Joo-Young Kim, Young Kwok, Nadia N Laack, Choonsik Lee, Do Hoon Lim, Lilia Loredo, Victor S Mangona, David B Mansur, Masao Murakami, Shigeyuki Murayama, Takashi Ogino, Barbora Ondrová, Rahul R Parikh, Arnold C Paulino, Stephanie Perkins, Naren R Ramakrishna, Ronald Richter, Barbara Rombi, Satoshi Shibata, Shinichi Shimizu, Beate Timmermann, Tamara Vern-Gross, Chiachien J Wang, Damien C Weber, John Ben Wilkinson, Petra Witt Nyström, Torunn I Yock, Ruth A Kleinerman, Amy Berrington de Gonzalez Patterns of proton therapy use in pediatric cancer management in 2016 An international survey CONCLUSION: To our knowledge, this survey provides the first worldwide assessment of proton therapy use for pediatric cancer management. Since previous estimates in the United States and Europe, CNS tumors remain the cancer types most commonly treated with protons in 2016. However, the proportion of... 11/12/2018
Simona F Shaitelman, Xiudong Lei, Alastair Thompson, Pamela Schlembach, Elizabeth S Bloom, Isidora Y Arzu, Daniel Buchholz, Gregory Chronowski, Tomas Dvorak, Emily Grade, Karen Hoffman, George Perkins, Valerie K Reed, Shalin J Shah, Michael C Stauder, Eric A Strom, Welela Tereffe, Wendy A Woodward, Diana N Amaya, Yu Shen, Gabriel N Hortobagyi, Kelly K Hunt, Thomas A Buchholz, Benjamin D Smith Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation Results of a Randomized, Noninferiority Clinical Trial CONCLUSION: Three years after WBI followed by a tumor bed boost, outcomes with hypofractionation and conventional fractionation are similar. Tumor bed boost, chemotherapy, and larger breast size do not seem to be strong contraindications to HF-WBI. 11/1/2018
Rafael Mañon, Veronica Schimp, Priya Gopalan, Kavita Pattani, Jennifer Tseng The Impact of HPV as an Etiological Factor in Gynecological and Oropharyngeal Cancer The human papilloma virus (HPV) is one of several viral pathogens linked to human cancer. This article reviews the current worldwide cancer burden related to this pathogen. The article also examines the role of HPV in oropharyngeal and gynecological malignancies, current treatment implications, and ... 9/12/2018
Shane R Stecklein, Simona F Shaitelman, Gildy V Babiera, Isabelle Bedrosian, Dalliah M Black, Matthew T Ballo, Isadora Arzu, Eric A Strom, Valerie K Reed, Tomas Dvorak, Benjamin D Smith, Wendy A Woodward, Karen E Hoffman, Pamela J Schlembach, Steve M Kirsner, Christopher L Nelson, Jinzhong Yang, William Guerra, Shiva Dibaj, Elizabeth S Bloom Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy CONCLUSIONS: Brachytherapy APBI is associated with higher rates of grade 1 fibrosis and seroma than 3-dimensional CRT but lower rates of grade 1 edema and grade 2 to 3 pain than 3-dimensional CRT. Rates of radiation oncologist-reported fair or poor cosmetic outcomes are higher with brachytherapy. We... 8/21/2018
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Francisco J Esteva, Sharon H Giordano, Jeffrey J Kirshner, Ian E Krop, Jennifer Levinson, Shanu Modi, Debra A Patt, Jane Perlmutter, Eric P Winer, Nancy U Lin Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases ASCO Clinical Practice Guideline Update Purpose To update the formal expert consensus-based guideline recommendations for practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2-positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted s... 6/26/2018
Sharon H Giordano, Sarah Temin, Sarat Chandarlapaty, Jennie R Crews, Francisco J Esteva, Jeffrey J Kirshner, Ian E Krop, Jennifer Levinson, Nancy U Lin, Shanu Modi, Debra A Patt, Jane Perlmutter, Naren Ramakrishna, Eric P Winer, Nancy E Davidson Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer ASCO Clinical Practice Guideline Update Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (f... 6/26/2018
Renata Ferrarotto, William N William, Jennifer E Tseng, Shanthi Marur, Dong M Shin, Barbara Murphy, Ezra E W Cohen, Christopher Y Thomas, Richard Willey, Jan Cosaert, Nusrat Harun, J Jack Lee, Ignacio W Wistuba, Robert I Haddad, Bonnie S Glisson Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrentmetastatic head and neck squamous cell carcinoma CONCLUSION: The results of this study do not support the use of cixutumumab alone or with cetuximab in unselected patients with R/M HNSCC. 6/19/2018
Gerard J Criner, Richard Sue, Shawn Wright, Mark Dransfield, Hiram Rivas-Perez, Tanya Wiese, Frank C Sciurba, Pallav L Shah, Momen M Wahidi, Hugo Goulart de Oliveira, Brian Morrissey, Paulo F G Cardoso, Steven Hays, Adnan Majid, Nicholas Pastis, Lisa Kopas, Mark Vollenweider, P Michael McFadden, Michael Machuzak, David W Hsia, Arthur Sung, Nabil Jarad, Malgorzata Kornaszewska, Stephen Hazelrigg, Ganesh Krishna, Brian Armstrong, Narinder S Shargill, Dirk-Jan Slebos, LIBERATE Study Group A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema LIBERATE CONCLUSIONS: Zephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.... 5/23/2018
Yuk Pheel Park, Linchun Jin, Katie B Bennett, Dunrui Wang, Kristianna M Fredenburg, Jennifer E Tseng, Lung-Ji Chang, Jianping Huang, Edward K L Chan CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma CONCLUSION: CD70-specific CAR-T cells specifically recognized and efficiently eliminated CD70-positive HNSCC cells. This study provides the basis for further investigation into CD70 and other CAR-T targets. 3/3/2018
Cameron W Swanick, Xiudong Lei, Ying Xu, Yu Shen, Nathan A Goodwin, Grace L Smith, Sharon H Giordano, Kelly K Hunt, Reshma Jagsi, Simona F Shaitelman, Susan K Peterson, Benjamin D Smith Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors A Population-Based Survey Study CONCLUSIONS: In this nationally diverse cohort, less irradiation and less surgery were associated with better long-term quality-of-life outcomes. However, patient regret regarding surgery and radiation therapy was similar across all groups. 2/28/2018
Virginia Wedell Osborn, Babak Givi, Justin Rineer, Dylan Roden, Niki Sheth, Ariel Lederman, Evangelia Katsoulakis, Kenneth Hu, David Schreiber Patterns of care and outcomes of adjuvant therapy for high-risk head and neck cancer after surgery CONCLUSION: Postoperative CRT seems underutilized with positive margins and/or ECE and overutilized without positive margins and/or ECE. The CRT was associated with improved OS but the benefit persisted only in the subset with positive margins and/or ECE. 2/17/2018
Shannon E Fogh, Snehal Deshmukh, Lawrence B Berk, Amylou C Dueck, Kevin Roof, Sherif Yacoub, Thomas Gergel, Kevin Stephans, Andreas Rimner, Albert DeNittis, John Pablo, Justin Rineer, Terence M Williams, Deborah Bruner A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer Results of NRG Oncology RTOG 1012 CONCLUSION: Honey as prescribed within this protocol was not superior to best supportive care in preventing radiation esophagitis. Further testing of other types of honey and research into the mechanisms of action are needed. 3/1/2017
Joanne B Weidhaas, Jonathan Harris, Dörthe Schaue, Allen M Chen, Robert Chin, Rita Axelrod, Adel K El-Naggar, Anurag K Singh, Thomas J Galloway, David Raben, Dian Wang, Chance Matthiesen, Vilija N Avizonis, Rafael R Manon, Omar Yumen, Phuc Felix Nguyen-Tan, Andy Trotti, Heath Skinner, Qiang Zhang, Robert L Ferris, David Sidransky, Christine H Chung The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer A Secondary Analysis of a Randomized Clinical Trial CONCLUSIONS AND RELEVANCE: Patients with the KRAS-variant with HNSCC significantly benefit from the addition of cetuximab to radiotherapy and cisplatin, and there is a significant interaction between the KRAS-variant and p16 status. Elevated TGF-β1 levels in patients with the KRAS-variant suggests t... 12/23/2016
Andrew T Wong, Meng Shao, Justin Rineer, Virginia Osborn, David Schwartz, David Schreiber Treatment and survival outcomes of small cell carcinoma of the esophagus an analysis of the National Cancer Data Base Given the paucity of esophageal small cell carcinoma (SCC) cases, there are few large studies evaluating this disease. In this study, the National Cancer Data Base (NCDB) was utilized to analyze the clinical features, treatment, and survival of patients with esophageal SCC in a large, population-bas... 11/19/2016
Andrew T Wong, Justin Rineer, David Schwartz, Joseph Weiner, Joseph Safdieh, Kwang Choi, David Schreiber Patterns of adjuvant radiation usage and survival outcomes for stage I endometrial carcinoma in a large hospital-based cohort CONCLUSION: The use of adjuvant RT for women with stage I EC is highly dependent on stage/grade and is associated with improved survival for stage IB. 11/9/2016
Andrew T Wong, Justin Rineer, David Schwartz, Daniel Becker, Joseph Safdieh, Virginia Osborn, David Schreiber Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma CONCLUSION: These data support the early initiation of hyperfractionated thoracic RT for nonmetastatic SCLC. 10/1/2016
Asim Amin, David H Lawson, April K S Salama, Henry B Koon, Troy Guthrie, Sajeve S Thomas, Steven J O'Day, Montaser F Shaheen, Bin Zhang, Stephen Francis, F Stephen Hodi Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma CONCLUSIONS: VEM (960 mg twice daily for 6 weeks) followed by IPI 10 mg/kg has a manageable safety profile. The benefits/risks of BRAF inhibitors followed by immunotherapy should be evaluated further in light of continuing developments in treatment options for metastatic melanoma. 8/18/2016
Andrew T Wong, Justin Rineer, Yi-Chun Lee, David Schwartz, Joseph Safdieh, Joseph Weiner, Kwang Choi, David Schreiber Utilization of adjuvant therapies and their impact on survival for women with stage IIIC endometrial adenocarcinoma CONCLUSIONS: Both adjuvant CT and adjuvant RT were associated with improved OS for women with stage IIIC endometrial adenocarcinoma, but CMT was associated with the largest improvement in OS. 7/17/2016
Cameron W Swanick, Xiudong Lei, Simona F Shaitelman, Pamela J Schlembach, Elizabeth S Bloom, Michelle C Fingeret, Eric A Strom, Welela Tereffe, Wendy A Woodward, Michael C Stauder, Tomas Dvorak, Alastair M Thompson, Thomas A Buchholz, Benjamin D Smith Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation CONCLUSIONS: In this randomized trial, longitudinal outcomes did not appear to differ by treatment arm. Patient-reported functional and pain outcomes improved over time. These findings are relevant when counseling patients regarding decisions concerning radiotherapy. Cancer 2016. © 2016 American Can... 6/16/2016
Andrew T Wong, Meng Shao, Justin Rineer, Anna Lee, David Schwartz, David Schreiber The Impact of Adjuvant Postoperative Radiation Therapy and Chemotherapy on Survival After Esophagectomy for Esophageal Carcinoma CONCLUSIONS: In this hospital-based study, the addition of postoperative chemoradiation (either sequentially or concomitantly) after esophagectomy was associated with improved OS for patients with node-positive disease or positive margins. 6/10/2016
Raquibul Hannan, Vasu Tumati, Xian-Jin Xie, L Chinsoo Cho, Brian D Kavanagh, Jeffrey Brindle, David Raben, Akash Nanda, Susan Cooley, D W Nathan Kim, David Pistenmaa, Yair Lotan, Robert Timmerman Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial CONCLUSION: SBRT treatment results in excellent biochemical control rates at 5 years for LR and IR PCa patients although doses greater than 47.5 Gy in five fractions led to increased severe late toxicity. 4/2/2016
Andrew T Wong, Justin Rineer, David Schwartz, David Schreiber Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stage Small Cell Lung Cancer Using the National Cancer Database CONCLUSION: The use of PORT was associated with a deleterious effect on OS in patients with pN0 disease but significantly improved OS in patients with pN2 disease. 2/5/2016
Michael Phillips, Thomas L Bauer, Renee N Cataneo, Cassie Lebauer, Mayur Mundada, Harvey I Pass, Naren Ramakrishna, William N Rom, Eric Vallières Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening CONCLUSIONS: Breath VOC mass ion biomarkers identified lung cancer in a separate independent cohort, in a blinded replicated study. Combining breath biomarkers with chest CT could potentially improve the sensitivity and specificity of lung cancer screening. 12/25/2015
Joseph J Safdieh, David Schwartz, Justin Rineer, Joseph P Weiner, Andrew Wong, David Schreiber Does the Presence of a Major Psychiatric Disorder Affect Tolerance and Outcomes in Men With Prostate Cancer Receiving Radiation Therapy Prior studies have suggested that men with prostate cancer and psychiatric disorders (+Psy) have worse outcomes compared with those without (-Psy), particularly due to delayed diagnosis or reduced access to definitive treatment. In the current study, the toxicity and outcomes of men who were primari... 10/22/2015
David Schreiber, Andrew T Wong, David Schwartz, Justin Rineer Utilization of Hyperfractionated Radiation in Small-Cell Lung Cancer and Its Impact on Survival CONCLUSIONS: The adoption of BID radiation remains very limited, but is more commonly utilized in the academic setting. In this hospital-based study, BID fractionation was associated with improved survival over once-daily fractionation, even at doses ≥60 Gy. 9/4/2015
Andrew T Wong, Joseph J Safdieh, Justin Rineer, Joseph Weiner, David Schwartz, David Schreiber A population-based analysis of contemporary patterns of care in younger men lt;60 years old with localized prostate cancer CONCLUSIONS: A significant proportion of younger men diagnosed with localized prostate cancer, particularly with low- or high-risk disease, are not receiving definitive therapy. African-American men, uninsured men, and patients with Medicaid or no medical insurance are less likely to receive definit... 9/3/2015
Lior Z Braunstein, Ming-Hui Chen, Daniel E Dosoretz, Sharon A Salenius, Michael J Katin, Akash Nanda, Anthony V D'Amico Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk CONCLUSION: Treatment with WPRT or short-course ADT is associated with a decreased risk of ACM, although a combination of the two does not yield greater benefit. This observation suggests a shared mechanism for this risk reduction, which we hypothesize to be via the treatment of micrometastatic dise... 5/25/2015
Alexander N Starodub, Allyson J Ocean, Manish A Shah, Michael J Guarino, Vincent J Picozzi, Linda T Vahdat, Sajeve S Thomas, Serengulam V Govindan, Pius P Maliakal, William A Wegener, Steven A Hamburger, Robert M Sharkey, David M Goldenberg First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors CONCLUSIONS: Sacituzumab govitecan had acceptable toxicity and encouraging therapeutic activity in patients with difficult-to-treat cancers. The 8 and 10 mg/kg doses were selected for phase II studies. 5/7/2015
David Schreiber, Justin Rineer, Jeffrey P Weiss, Joseph Safdieh, Joseph Weiner, Marvin Rotman, David Schwartz Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer CONCLUSION: Treatment approaches utilizing RRP +/- salvage radiation or RT +/- androgen deprivation yielded equivalent DMPFS and PCSS outcomes. Biochemical control rates, using their respective definitions, appeared equivalent or better in those who received treatment with RT. 4/16/2015
David Schreiber, Arpit Chhabra, Justin Rineer, Jeremy Weedon, David Schwartz A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer Does African-American Race Predict for More Aggressive Disease CONCLUSION: In the absence of definitive data to support a more aggressive natural history of very low risk prostate cancer in AA men, these data support continued use of active surveillance in this population. 3/18/2015
David Schreiber, Andrew T Wong, Justin Rineer, Jeremy Weedon, David Schwartz Prostate biopsy concordance in a large population-based sample a Surveillance, Epidemiology and End Results study CONCLUSIONS: This study is, to our knowledge, the largest contemporary study of prostate biopsy concordance. We found that there continues to be significant Gleason migration both upward from biopsy Gleason 6 or 3+4 and downgrading from biopsy Gleason ≥8. Further studies are needed to better determi... 3/13/2015
Ami B Raval, Jennifer Salluzzo, Tomas Dvorak, Lori Lyn Price, John E Mignano, Julian K Wu Salvage Gamma Knife Radiosurgery after failed management of bilateral trigeminal neuralgia CONCLUSION: Bilateral TN is rare, and effective treatment is crucial to improve the quality of life of those afflicted. Salvage GKRS is a reasonable treatment modality for individuals with bilateral TN. 12/20/2014
David Schreiber, Shan-Chin Chen, Justin Rineer, Matthew Worth, Tejas Telivala, David Schwartz Assessment of risk of late rectal bleeding for patients with prostate cancer started on anticoagulation before or after radiation treatment CONCLUSION: The use of clopidogrel or warfarin during radiation is associated with significantly increased risk of rectal bleeding. However, initiation of these medications after completion of radiation does not appear to impact such risk. 12/16/2014
Joseph J Safdieh, David Schwartz, Joseph Weiner, Jeffrey P Weiss, Justin Rineer, Isaac Madeb, Marvin Rotman, David Schreiber Long-term tolerance and outcomes for dose escalation in early salvage post-prostatectomy radiation therapy CONCLUSION: In this series with long-term follow-up, early SRT provided outcomes and toxicity profiles similar to those reported from the three major randomized trials studying adjuvant radiation therapy. 10/18/2014
David Schreiber, Justin Rineer, Aparna Surapaneni, Elliot Navo, Manuj Agarwal, Emmanuel Nwokedi, Marvin Rotman, David Schwartz Dose-escalated radiation therapy with and without short-course androgen deprivation for intermediate-risk prostate cancer CONCLUSION: Dose-escalated RT and short-course ADT results in improved biochemical outcomes for IR prostate cancer. 7/31/2014
Lucy Harn Kapur, Yasser Khaled, Melhem Solh, David Ward, Chung-Che Chang De novo CD3 negative hepatosplenic T-cell lymphoma diagnostic challenges and pitfalls Hepatosplenic T-cell lymphoma is a rare and aggressive peripheral T-cell malignancy that is distinctively characterized by sinusoidal infiltration of mature medium-sized T lymphocytes in the spleen and liver. The neoplastic cells are classically surface CD3(+), CD2(+), CD5(-), CD4(-), and CD8(+/-) a... 7/1/2014
D W Nathan Kim, L Chinsoo Cho, Christopher Straka, Alana Christie, Yair Lotan, David Pistenmaa, Brian D Kavanagh, Akash Nanda, Patrick Kueplian, Jeffrey Brindle, Susan Cooley, Alida Perkins, David Raben, Xian-Jin Xie, Robert D Timmerman Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer CONCLUSION: Caution is advised when considering high-dose SBRT for treatment of tumors near bowel structures, including prostate cancer. Threshold dose constraints developed from physiologic principles are defined, and if respected can minimize risk of severe rectal toxicity. 6/15/2014
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Francisco J Esteva, Sharon H Giordano, Ana M Gonzalez-Angulo, Jeffrey J Kirshner, Ian Krop, Jennifer Levinson, Shanu Modi, Debra A Patt, Edith A Perez, Jane Perlmutter, Eric P Winer, Nancy U Lin Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases American Society of Clinical Oncology clinical practice guideline PURPOSE: To provide formal expert consensus-based recommendations to practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. 5/7/2014
Sharon H Giordano, Sarah Temin, Jeffrey J Kirshner, Sarat Chandarlapaty, Jennie R Crews, Nancy E Davidson, Francisco J Esteva, Ana M Gonzalez-Angulo, Ian Krop, Jennifer Levinson, Nancy U Lin, Shanu Modi, Debra A Patt, Edith A Perez, Jane Perlmutter, Naren Ramakrishna, Eric P Winer, American Society of Clinical Oncology Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer American Society of Clinical Oncology clinical practice guideline PURPOSE: To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. 5/7/2014
Benjamin J Waghorn, Amish P Shah, Justin M Rineer, Katja M Langen, Sanford L Meeks A margin-based analysis of the dosimetric impact of motion on step-and-shoot IMRT lung plans CONCLUSIONS: Targets moving in excess of 5 mm outside the margin can cause significant changes to the target. D95% decreased by up to 20% with target motion 10 mm outside the margin, with underdosing primarily limited to the target periphery. Multi-fractionated treatments were found to exacerbate ta... 2/7/2014
Tomas Dvorak, Markus M Fitzek, David E Wazer Utilization of proton therapy evidence-based, market-driven, or something in-between CONCLUSIONS: The degree of PT utilization would depend on the strictness of selection criteria, and would likely range from 6% to 25%, with concomitant cost increase from minimal to 40%. Ultimate adoption of PT in the United States may depend on individual facilities and payors performing similar an... 3/7/2012